Platelet-rich plasma (PRP)

Platelet-rich plasma (PRP) is an autologous biologic mixture prepared by centrifuging a patient's own blood to obtain a concentrated suspension of platelets (StatPearls: NBK531483). It is not a single molecular target but a therapeutic agent that delivers a high density of growth factors and bioactive proteins to injured tissues. These components, such as platelet-derived growth factor (PDGF) and transforming growth factor-beta (TGF-beta), are essential for the recruitment and proliferation of mesenchymal stem cells and fibroblasts (PubMed: 21865995). PRP is widely utilized in sports medicine, orthopedics, and dermatology to treat conditions like tendinopathy, osteoarthritis, and hair loss. Upon injection, platelets are activated by endogenous collagen or added thrombin, triggering the release of these regenerative factors. However, its clinical efficacy is often debated due to significant heterogeneity in preparation methods and platelet concentrations across different systems (PubMed: 30343456). It is generally considered safe due to its autologous nature, minimizing the risk of immune rejection or disease transmission. The mixture acts as a scaffold and a signaling hub, modulating the inflammatory environment to favor tissue repair over fibrosis.

Other names

Autologous platelet-rich plasmaPlatelet-rich concentratePlatelet gelAutologous conditioned plasma

Platelet-rich plasma functions by releasing a concentrated cocktail of growth factors and cytokines from platelet alpha-granules upon activation at the site of injury. These factors, including PDGF, TGF-beta, and VEGF, bind to specific receptors on target cells to initiate signaling cascades that promote chemotaxis, angiogenesis, and extracellular matrix synthesis, thereby accelerating the natural healing process (StatPearls: NBK531483).